세계의 만성 부비동염 시장 - 인사이트, 역학, 예측(2034년)

Key Highlights:

• Chronic rhinosinusitis is a prolonged inflammation of the nose and paranasal sinuses lasting 12 weeks or more, despite treatment. It involves at least two symptoms nasal blockage, discharge, facial pain/pressure, or loss of smell along with objective findings on imaging or nasal endoscopy.
• According to secondary sources, chronic rhinosinusitis shows higher prevalence among smokers than non-smokers, individuals with obesity compared to those with normal weight, and in patients with comorbid conditions such as asthma, diabetes mellitus, eczema, and nasal septal deviation.
• The Chronic Rhinosinusitis market is anticipated to experience steady growth from 2025 to 2034, driven by increasing disease awareness, a rising prevalence of upper airway inflammatory disorders, improved diagnostic capabilities, and advancements in biologic therapies. Continued innovation in treatment modalities and a strong clinical research pipeline are expected to support the market's ongoing expansion.
• DUPIXENT (dupilumab), developed by Regeneron and Sanofi, and NUCALA (mepolizumab), developed by GlaxoSmithKline, are innovative biologic therapies approved for the treatment of chronic rhinosinusitis with nasal polyps. DUPIXENT works by blocking interleukin-4 and interleukin-13 signaling to reduce type 2 inflammation, while NUCALA targets interleukin-5 to decrease eosinophilic activity. These approvals represent a shift toward personalized, immune-targeted treatments for patients with chronic rhinosinusitis with nasal polyps.
• Lyra Therapeutics is one of several companies developing treatment options for chronic rhinosinusitis. Its pipeline includes LYR-210 and LYR-220, which are bioabsorbable nasal mesh that deliver sustained-release mometasone furoate for up to six months. LYR-210 is for patients with intact sinus anatomy, while LYR-220 targets those post-surgery. These therapies reflect a broader industry shift toward long-acting, localized treatments aimed at reducing disease burden and improving patient outcomes.
• In May 2025, Lyra Therapeutics presented the 52-week extension stage results from the ENLIGHTEN 1 Phase III study evaluating LYR-210 for the treatment of chronic rhinosinusitis at Combined Otolaryngology Spring Meetings (COSM 2025).
• Market growth in chronic rhinosinusitis is driven by advanced therapies and innovative drug delivery technologies that target persistent inflammation and symptom burden. While conventional treatments like nasal corticosteroids, antibiotics, and surgery remain standard, issues such as recurrence and antibiotic resistance highlight the need for more effective, long-lasting solutions. Emerging treatments aim to improve outcomes, reduce relapses, and enhance quality of life through sustained symptom control.

DelveInsight's comprehensive report titled "Chronic Rhinosinusitis - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of chronic rhinosinusitis. The report presents historical and projected epidemiological data covering total prevalent cases of chronic rhinosinusitis, total diagnosed prevalent cases of chronic rhinosinusitis, gender-specific cases of chronic rhinosinusitis, age-specific cases of chronic rhinosinusitis, type-specific cases of chronic rhinosinusitis and treated cases of chronic rhinosinusitis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in chronic rhinosinusitis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Chronic Rhinosinusitis Overview

Chronic rhinosinusitis is a persistent inflammatory condition affecting the paranasal sinuses, often resulting in a considerable decline in an individual's quality of life. This condition can cause prolonged discomfort and interfere with daily functioning due to ongoing symptoms and the chronic nature of the inflammation. Chronic rhinosinusitis can be classified according to the presence of a nasal polyp: chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyp.

Clinically, chronic rhinosinusitis is defined by the presence of at least two out of four primary symptoms-facial pain or pressure, nasal congestion or obstruction, nasal discharge (anterior or posterior), and a diminished or lost sense of smell (hyposmia or anosmia), lasting for a continuous period of 12 weeks or longer. These symptoms must be supported by objective findings of inflammation, which can be observed through a physical.

Chronic Rhinosinusitis Diagnosis and Treatment Algorithm

Chronic rhinosinusitis is diagnosed through a detailed physical examination and clinical history, focusing on associated symptoms and comorbidities. Nasal obstruction is the most commonly reported symptom, followed by facial pressure, nasal discharge, and loss of smell. Physical examination helps confirm diagnosis by identifying signs like mucopurulent drainage, turbinate hypertrophy, septal deviation, or polyps.

For imaging, non-contrast-enhanced sinus computed tomography (CT) is the gold standard and is preferred over plain radiography due to higher diagnostic accuracy. CT scans are safe and should only be ordered in patients meeting symptom criteria to reduce false positives. In primary care settings, sinus CT can serve as a substitute for endoscopy, enabling prompt diagnosis and management. When surgical intervention is considered, properly specified CT scans can prevent the need for repeat imaging, making early imaging both effective and cost-efficient.

Chronic rhinosinusitis treatment focuses on symptom relief, reducing inflammation, and improving sinus drainage. First-line therapies include daily isotonic saline irrigation and intranasal corticosteroids, which are effective in improving symptoms and quality of life. Oral corticosteroids may offer short-term relief in severe cases, particularly with nasal polyps, but must be used cautiously. Antibiotics are reserved for cases with confirmed infection, though evidence for their benefit remains limited.

If medical therapy fails, endoscopic sinus surgery may be considered to enhance sinus drainage and medication delivery, though it is not curative and requires ongoing medical management. Acute exacerbations are typically managed with observation, corticosteroids, or antibiotics, though benefits over placebo are minimal. Referral to specialists is recommended for patients with comorbidities or poor response to initial treatment.

Chronic Rhinosinusitis Epidemiology

The epidemiology section of the chronic rhinosinusitis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of chronic rhinosinusitis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to secondary sources, the global pooled prevalence of chronic rhinosinusitis is estimated at 8.71%. The condition is more prevalent in Europe than in America and Asia, and occurs more frequently among adults than children.
• According to secondary research, chronic rhinosinusitis with nasal polyps affects approximately 1.1% of adults in the United States.
• A retrospective, comparative cohort study examining the real-world burden and treatment of chronic rhinosinusitis in Japan found that the condition affects approximately 1%-6% of individuals when diagnosed using CT scans and nasal endoscopy, and up to 13% based on symptom-based diagnosis. It is most prevalent among middle-aged adults, with a mean age of 45 years, and occurs more frequently in males, accounting for 57% of cases.
• The epidemiology of chronic rhinosinusitis is expected to change during the forecast period (2025-2034).

Chronic Rhinosinusitis Market Outlook

The chronic rhinosinusitis therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the chronic rhinosinusitis market in the 7MM is expected to change significantly during the forecast period 2025-2034.

Chronic Rhinosinusitis Drug Chapters

Marketed Chronic Rhinosinusitis Drugs

DUPIXENT (dupilumab): Regeneron and Sanofi

DUPIXENT (dupilumab) is a fully-human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a central role in type 2 inflammation. It is given as a subcutaneous injection every other week at different injection sites. DUPIXENT is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis

In June 2019, the US FDA approved DUPIXENT (dupilumab) for chronic rhinosinusitis with Nasal Polyposis.

In October 2019, the European Commission has granted approval of DUPIXENT (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis.

NUCALA (mepolizumab): GSK

NUCALA (mepolizumab) is the first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.

In July 2021, US FDA has approved NUCALA (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps.

In November 2021, the European Commission has approved NUCALA (mepolizumab) as an add-on treatment for chronic rhinosinusitis with nasal polyps.

Emerging Chronic Rhinosinusitis Drugs

The chronic rhinosinusitis market is expected to evolve gradually. Key players such as LYR-210 and LYR-220, by Lyra therapeutics among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

LYR-210: Lyra Therapeutics

LYR-210 is a bioabsorbable nasal mesh designed for administration during a short, in-office procedure. It provides continuous delivery of the anti-inflammatory medication mometasone furoate to the sinonasal passages for up to six months, aiming to treat chronic rhinosinusitis. LYR-210, is in Phase III development for chronic rhinosinusitis patients who have failed current treatments and require further intervention.

In June 2025, Lyra Therapeutics reported positive results from the ENLIGHTEN 2 Phase III trial of LYR-210, achieving statistically significant outcomes for both the primary and key secondary endpoints in the treatment of chronic rhinosinusitis.

LYR-220: Lyra Therapeutics

LYR-220, is in Phase II development for chronic rhinosinusitis patients who have undergone a prior sinus surgery but continue to have persistent disease. LYR-220 is sized for patients whose nasal cavity is enlarged due to sinus surgery.

Like LYR-210 but larger, LYR-220 is a bioabsorbable nasal mesh administered in a brief in-office procedure. LYR-220 is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages of CRS patients with post-surgical anatomy. LYR-220 is being evaluated in the BEACON Phase II clinical trial.

Chronic Rhinosinusitis Market Segmentation

DelveInsight's 'Chronic Rhinosinusitis- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future chronic rhinosinusitis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Chronic Rhinosinusitis Market Size by Countries

The chronic rhinosinusitis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) chronic rhinosinusitis market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Chronic Rhinosinusitis Market Size by Therapies

Chronic Rhinosinusitis Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034.

Chronic Rhinosinusitis Drugs Uptake

This section focuses on the sales uptake of potential chronic rhinosinusitis drugs that have recently been launched or are anticipated to be launched in the chronic rhinosinusitis market between 2020 and 2034. It estimates the market penetration of chronic rhinosinusitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the chronic rhinosinusitis market.

The emerging chronic rhinosinusitis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the chronic rhinosinusitis market.

Chronic Rhinosinusitis Market Access and Reimbursement

DelveInsight's 'Chronic Rhinosinusitis- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of chronic rhinosinusitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current chronic rhinosinusitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the chronic rhinosinusitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or chronic rhinosinusitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the chronic rhinosinusitis unmet needs.

Chronic Rhinosinusitis: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Stanford University School of Medicine, US, University Hospital Marburg, Germany, University of Barcelona, Spain, Universite Paris-Saclay, France, Cambridge University, UK, and Toho University Ohashi Medical Center, Japan, among others.

"Chronic rhinosinusitis is commonly managed with medications such as low-dose macrolides, intranasal corticosteroids, and short-term systemic corticosteroids. For individuals with chronic rhinosinusitis with nasal polyps who do not respond to these treatments, endoscopic sinus surgery (ESS) is typically performed."

"Biologic therapies are increasingly being explored as treatment options for patients with chronic rhinosinusitis with nasal polyps who do not respond adequately to intranasal corticosteroids. They are particularly considered for individuals who are not suitable candidates for surgery, have experienced recurrence or are at high risk of recurrence after nasal polyp surgery, or have coexisting type 2 inflammatory conditions like asthma."

"Imaging studies like sinus CT should be reserved for patients who present with at least two symptoms suggestive of chronic rhinosinusitis, due to the high rate of false positives in detecting sinonasal abnormalities. For instance, mucosal thickening seen in the paranasal sinuses could simply reflect changes from a recent viral upper respiratory infection, which may persist on imaging for several weeks."

Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the chronic rhinosinusitis market, utilizing various competitive intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Chronic Rhinosinusitis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for chronic rhinosinusitis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging chronic rhinosinusitis therapies.

Chronic Rhinosinusitis Report Insights

• Chronic Rhinosinusitis Patient Population
• Therapeutic Approaches
• Chronic Rhinosinusitis Pipeline Analysis
• Chronic Rhinosinusitis Market Size and Trends
• Chronic Rhinosinusitis Market Opportunities
• Impact of Upcoming Therapies

Chronic Rhinosinusitis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Chronic Rhinosinusitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Chronic rhinosinusitis Market
• Chronic Rhinosinusitis Drugs Uptake

Chronic Rhinosinusitis Report Assessment

• Chronic Rhinosinusitis Current Treatment Practices
• Unmet Needs
• Chronic Rhinosinusitis Pipeline Product Profiles
• Chronic Rhinosinusitis Market Attractiveness

Key Questions:

• How common is chronic rhinosinusitis?
• What are the key findings of chronic rhinosinusitis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for chronic rhinosinusitis?
• What are the disease risk, burden, and unmet needs of chronic rhinosinusitis?
• At what CAGR is the chronic rhinosinusitis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the chronic rhinosinusitis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of chronic rhinosinusitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of chronic rhinosinusitis?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic rhinosinusitis Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for chronic rhinosinusitis?

The primary goals in treating chronic rhinosinusitis are to reduce inflammation, restore normal sinus drainage, and improve mucociliary clearance. Treatment aims to alleviate key symptoms such as nasal congestion, facial pressure, loss of smell, and nasal discharge, while enhancing quality of life and reducing the frequency of acute exacerbations. Long-term management also focuses on preventing disease recurrence and minimizing the need for systemic medications or surgical intervention.

2. What are the challenges in managing chronic rhinosinusitis?

Managing chronic rhinosinusitis is challenging due to its varied causes, overlapping symptoms, and frequent recurrence. Differentiating between phenotypes, such as with or without nasal polyps, requires individualized treatment strategies. Long-term management is complicated by comorbidities like asthma, limited access to advanced therapies such as biologics, and issues with treatment adherence and cost. These factors make effective, sustained disease control difficult.

3. What are the key factors driving the growth of the chronic rhinosinusitis market?

Key factors driving the growth of the chronic rhinosinusitis market include increased awareness and diagnosis of the condition, rising prevalence of comorbidities like asthma and allergies, and a growing demand for long-acting and targeted therapies. The approval of novel biologics and implantable drug delivery systems has expanded treatment options, especially for patients unresponsive to conventional therapy. Additionally, improved diagnostic tools, greater focus on quality of life, and favorable reimbursement trends are contributing to market expansion.

4. How will the chronic rhinosinusitis Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current chronic rhinosinusitis market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution by Therapies in 2024
• 3.2. Market Share (%) Distribution by Therapies in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Prevalent Cases of Chronic Rhinosinusitis in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM
• 8.5. The US
  • 8.5.1. Total Prevalent Cases of Chronic Rhinosinusitis
  • 8.5.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • 8.5.3. Gender-specific Cases of Chronic Rhinosinusitis
  • 8.5.4. Age-specific Cases of Chronic Rhinosinusitis
  • 8.5.5. Type-specific Cases of Chronic Rhinosinusitis
  • 8.5.6. Treated Cases of Chronic Rhinosinusitis
• 8.6. EU4 and the UK
  • 8.6.1. Total Prevalent Cases of Chronic Rhinosinusitis
  • 8.6.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • 8.6.3. Gender-specific Cases of Chronic Rhinosinusitis
  • 8.6.4. Age-specific Cases of Chronic Rhinosinusitis
  • 8.6.5. Type-specific Cases of Chronic Rhinosinusitis
  • 8.6.6. Treated Cases of Chronic Rhinosinusitis
• 8.7. Japan
  • 8.7.1. Total Prevalent Cases of Chronic Rhinosinusitis
  • 8.7.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • 8.7.3. Gender-specific Cases of Chronic Rhinosinusitis
  • 8.7.4. Age-specific Cases of Chronic Rhinosinusitis
  • 8.7.5. Type-specific Cases of Chronic Rhinosinusitis
  • 8.7.6. Treated Cases of Chronic Rhinosinusitis

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. DUPIXENT (dupilumab): Regeneron and Sanofi
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. NUCALA (mepolizumab): GSK
  • 10.3.1. Drug Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. LYR-210: Lyra Therapeutics
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views
• 11.3. LYR-220: Lyra Therapeutics
  • 11.3.1. Drug Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' Views

12. Chronic Rhinosinusitis: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Chronic Rhinosinusitis in the 7MM
• 12.6. Market Size of Chronic Rhinosinusitis by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Chronic Rhinosinusitis
  • 12.7.2. Market Size of Chronic Rhinosinusitis by Therapies
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Chronic Rhinosinusitis
  • 12.8.2. Market Size of Chronic Rhinosinusitis by Therapies
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Chronic Rhinosinusitis
  • 12.9.2. Market Size of Chronic Rhinosinusitis by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Chronic Rhinosinusitis Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight